Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21538798 | 0.92 | CASP2 (0.43) | CASP2HPGDALDH1A1TSHRHDAC3 | |
| SCHEMBL20362595 | 0.89 | CASP2 (0.47) | CASP2HPGDALDH1A1HDAC3HDAC1 | |
| SCHEMBL23772072 | 0.86 | CASP2 (0.44) | CASP2HPGDALDH1A1HDAC3HDAC1 | |
| SCHEMBL21538817 | 0.86 | CASP2 (0.44) | CASP2HPGDALDH1A1HDAC3HDAC1 | |
| SCHEMBL22923595 | 0.85 | CASP2 (0.38) | CASP2HPGDALDH1A1TSHRNAAA | |
| SCHEMBL20920773 | 0.84 | CASP2 (0.37) | CASP2ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL22349877 | 0.84 | CASP2 (0.37) | CASP2HPGDALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL23919438 | 0.82 | MEN1 (0.45) | — | |
| SCHEMBL24340774 | 0.82 | CNR1 (0.40) | CASP2HPGDALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL27383010 | 0.81 | GAA (0.40) | CASP2HPGDALDH1A1TSHRNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275065-A1 | METHODS AND COMPOUNDS FOR DETECTING BETA-LACTAMASE ACTIVITY | NANYANG TECHNOLOGICAL UNIVERSITY | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275065-A1 | METHODS AND COMPOUNDS FOR DETECTING BETA-LACTAMASE ACTIVITY | LPO, MPO, GUSB | CASP2 2057/4885HPGD 3309/4885ALDH1A1 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.